PARP Inhibitor Biomarkers Market Research Report By Cancer Type (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Other Cancers), By Biomarker Type (BRCA Mutations, PARP Expression, HRD Score, Other Biomarkers), By Application (Diagnosis, Prognosis, Treatment Selection, Monitoring, Other Applications), By End User (Hospitals, Diagnostic Laboratories, Pharmaceutical Companies, Research Institutions, Other End Users), By Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (F

Global PARP Inhibitor Biomarkers Market Overview

As per MRFR analysis, the PARP Inhibitor Biomarkers Market Size was estimated at 2.64 (USD Billion) in 2022. The PARP Inhibitor Biomarkers Market Industry is expected to grow from 3.0(USD Billion) in 2023 to 9.5 (USD Billion) by 2032. The PARP Inhibitor Biomarkers Market CAGR (growth rate) is expected to be around 13.65% during the forecast period (2024 - 2032).

Key PARP Inhibitor Biomarkers Market Trends Highlighted

Several reasons, including increasing cancer incidences and increasing need for precision medicine, have a direct impact on the growth of the PARP Inhibitor Biomarkers Market. Growth in usage of molecular diagnostics and newer PARP Inhibitor Biomarkers further expanded the market. The potential lies in developing companion diagnostics & targeted therapy and in combinational approaches with PARP inhibitors.

Among these advances is the use of liquid biopsy techniques for undertaking biomarker elucidation, which makes monitoring less invasive and less expensive. Then, there is also work to seek out biomarkers that are related to the response to therapy and the emergence of resistance. There are challenges for the market, such as reimbursement and regulatory challenges, and all the stakeholders need to ensure sound scientific evidence is in place.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

PARP Inhibitor Biomarkers Market Drivers

Rising Prevalence of Cancer

The increasing prevalence of cancer worldwide is a major driving force behind the growth of the PARP Inhibitor Biomarkers Market Industry. As per the World Health Organization (WHO), approximately 19.3 million new cancer cases were diagnosed in 2020, and this number is projected to rise significantly in the coming years. The rising cancer burden is primarily attributed to factors such as aging populations, unhealthy lifestyles, and environmental pollution.PARP Inhibitor Biomarkers play a vital role in the diagnosis and treatment of various types of cancer, contributing to their growing demand in the market. By providing valuable information about the presence and activity of cancer cells, these biomarkers help clinicians make informed decisions regarding treatment strategies and patient prognosis, ultimately improving cancer outcomes.

Technological Advancements in Biomarker Discovery

The PARP Inhibitor Biomarkers Market Industry is experiencing accelerated growth due to the constant evolution of technologies used for biomarker discovery. The most recent advancements in bio-analytics, next-generation sequencing by F. Hoffmann-LA Roche, and multiplex immunoassays have significantly impacted the field of bio-analytics. Next-generation sequencing and multiplex immunoassays have allowed the field of research to discover a vast panorama of different types of biomarkers and, more importantly, develop the knowledge and tools necessary to accurately and reliably measure these biomarkers in extremely small blood or tissue samples.The ability to further progress in the field of early de novo cancer detection has, therefore, significantly impacted the market for PARP inhibitor biomarkers, resulting in their rapid growth.

Growing Adoption of Precision Medicine

Another major driver of the PARP Inhibitor Biomarkers Market Industry is the growing adoption of precision medicine. Precision medicine refers to the personalized medical treatment approach based on the individual biological features and characteristics of each patient, such as their biomarker and genomic profiles. Such features are crucial for teleoncology and telecancer techniques, for it helps to tailor the most effective treatment to the molecular subtype of cancer that is present in a patient.To do so, physicians identify such PARP Inhibitor Biomarkers, mutations, and alterations in the cancerous cells that best correlate with the response to specific types of treatment. As a result of this approach, doctors can then adjust treatment to the specific patient and not the overall, increasing its efficacy and reducing the risk of side effects. Therefore, the growing popularity of the precision medicine approach further drives the PARP Inhibitor Biomarkers Market Industry.

PARP Inhibitor Biomarkers Market Segment Insights:

PARP Inhibitor Biomarkers Market Cancer Type Insights

The PARP Inhibitor Biomarkers Market segmentation by Cancer Type includes Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, and Other Cancers. Of these, Breast Cancer has captured maximum market share and is expected to remain a revenue-generating segment for analysts in the forecast period. The increasing incidence and prevalence of breast cancer is one of the significant factors for this market segment’s market share. As per the American Cancer Society, in 2023, about 287,850 new diagnoses of invasive breast cancer are expected in the United States only.Ovarian Cancer, by type, is likely to gain substantial market CAGR throughout the forecast period. The expansion of this segment is due to the increasing incidence of ovarian cancer and the growing appetite for personalized treatment. Prostate Cancer, by type, is likely to witness a steady CAGR growth in the next years. In the Current Energy Market Report, analysts believe that the treatment of prostate cancer and the burgeoning age of first-time survivors could be critical factors feeding the appetite for these segments. Lung Cancer, by type, is expected to gain maximum market share due to the growing incidence of this cancer and the continued use of these new inhibitors in the treatment plan, thus delivering a high market CAGR. Other’ Cancers include pancreatic cancer, bladder cancer, and many other types of cancer. By type, the collective segment should gain a good market CAGR as the incidence of these cancers is growing rapidly, and the application of these inhibitors in these cancers cannot be overlooked. All markets combined, the PARP Inhibitor Biomarkers Market is expected to project a robust market CAGR. Such expansions are likely to be supported by a surge in overall cancer incidence, a growing taste for PARP inhibitors, and a slew of newly developed and innovative therapies based on these inhibitors.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

PARP Inhibitor Biomarkers Market Biomarker Type Insights

The PARP Inhibitor Biomarkers Market is segmented by Biomarker Type, which includes BRCA Mutations, PARP Expression, HRD Score, and Other Biomarkers. Among these, BRCA Mutations held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. This can be attributed to the high prevalence of BRCA mutations in cancer patients, particularly in breast and ovarian cancers. Additionally, the availability of targeted therapies for BRCA-mutated tumors has further driven the growth of this segment. PARP Expression is another significant segment, with a notable market share.PARP Expression testing helps identify patients who are more likely to respond to PARP inhibitors, leading to better treatment outcomes. The increasing adoption of PARP inhibitors in various cancer types is expected to fuel the growth of this segment in the coming years. The HRD Score segment is also gaining traction, owing to its ability to assess the genomic instability of tumors. HRD Score testing helps determine the likelihood of PARP inhibitor efficacy, providing valuable information for treatment decision-making. As the understanding of HRD and its correlation with PARP inhibitor response continues to evolve, this segment is poised for significant growth in the future.Other Biomarkers, which include various emerging biomarkers associated with PARP inhibitor response, represent a promising segment with potential for future growth. Ongoing research and advancements in biomarker discovery are expected to contribute to the expansion of this segment in the years to come.

PARP Inhibitor Biomarkers Market Application Insights

 The PARP Inhibitor Biomarkers Market is segmented by application into diagnosis, prognosis, treatment selection, monitoring, and other applications. The diagnosis segment accounted for the largest share of the market in 2023, and is projected to continue to grow at the highest CAGR during the forecast period. This growth is attributed to the increasing use of PARP inhibitors in the diagnosis of cancer, as well as the development of new and more sensitive diagnostic tests. The prognosis segment is also expected to grow significantly over the forecast period, as PARP inhibitors are increasingly used to predict the course of cancer and to guide treatment decisions.The treatment selection segment is expected to grow at a moderate pace, as PARP inhibitors are increasingly used to select the most appropriate treatment for each patient. The monitoring segment is expected to grow at a slow pace, as PARP inhibitors are increasingly used to monitor the response of cancer to treatment. The other applications segment is expected to grow at a steady pace, as PARP inhibitors are increasingly used in a variety of other applications, such as research and development.

PARP Inhibitor Biomarkers Market End User Insights

The end-user segment of the PARP Inhibitor Biomarkers Market plays a crucial role in determining market growth. Hospitals account for a significant share of the market due to the increasing incidence of cancer and the rising adoption of PARP inhibitor therapies. In 2023, the hospital segment is expected to generate revenue of around USD 1.2 billion and is projected to grow at a CAGR of 14.5% during the forecast period. Diagnostic laboratories represent another important end-user segment, with market revenue estimated to reach USD 850 million in 2023 and a projected CAGR of 13.8%.The growing demand for accurate and timely diagnosis of cancer drives the growth of this segment. Pharmaceutical companies also contribute to the market growth as they invest in research and development of PARP Inhibitor Biomarkers for companion diagnostics. Research institutions play a vital role in advancing the understanding of PARP Inhibitor Biomarkers through clinical trials and research studies. Their contributions drive innovation and the development of new biomarkers. Other end users, such as contract research organizations and academic institutions, also contribute to the growth of the PARP Inhibitor Biomarkers Market.

PARP Inhibitor Biomarkers Market Technology Insights

Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), Digital PCR, and Other Technologies are the major technologies used in the PARP Inhibitor Biomarkers Market. IHC is expected to hold the largest market share in 2023, owing to its wide adoption in clinical settings. NGS is expected to witness the highest growth rate during the forecast period, due to its increasing use in personalized medicine and cancer research. FISH and Digital PCR are also expected to contribute significantly to the market growth

PARP Inhibitor Biomarkers Market Regional Insights

The PARP Inhibitor Biomarkers Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest market for PARP Inhibitor Biomarkers, accounting for over 40% of the global revenue in 2023. The market in North America is driven by the high prevalence of cancer, the increasing adoption of precision medicine, and the presence of major pharmaceutical companies. Europe is the second largest market for PARP Inhibitor Biomarkers, with a market share of over 30%. The market in Europe is driven by the increasing awareness of personalized medicine and the growing number of cancer patients.APAC is the third largest market for PARP Inhibitor Biomarkers, with a market share of over 20%. The market in APAC is expected to grow rapidly in the coming years, driven by the increasing healthcare expenditure and the rising incidence of cancer. South America and MEA are relatively smaller markets for PARP Inhibitor Biomarkers, but they are expected to grow steadily in the coming years.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

PARP Inhibitor Biomarkers Market Key Players And Competitive Insights:

The leading companies in this industry are adopting various strategies to strengthen their position in the market. For example, they make investments in R&D, launch new products, form collaborations and engage in acquisitions and partnerships. The PARP Inhibitor Biomarkers Market is expected to expand considerably in the future due to the growing incidence of cancer and the increasing demand for personalized medicine.

AstraZeneca is a leading company that operates in this market. This company is expected to retain its leading position in the future due to its comprehensive portfolio of effective PARP inhibitors, including olaparib, niraparib, and rucaparib. The company is actively involved in the research and development of new products. AstraZeneca has several PARP inhibitors in the research and clinical trials stage.

Clovis Oncology is another major player, which is expected to strengthen its position on the PARP Inhibitor Biomarkers Market in the near future. This company’s PARP inhibitor rucaparib is already approved for the treatment of ovarian and breast cancer. Clovis Oncology is also developing several other PARP inhibitors, including amliparib and AR-42. The main competitor of AstraZeneca operating in this industry is Pfizer. Its Talzenna is already approved for the treatment of ovarian and breast cancer. Pfizer is also actively involved in the R of new drugs. It has several verter PARP inhibitors and related products, such as amliparib and AR-42, in the pipeline. Pfizer is a large global player with a very strong portfolio of cancer drugs.

Key Companies in the PARP Inhibitor Biomarkers Market Include:

• Illumina, Inc.


• Agilent Technologies


• Thermo Fisher Scientific


• PerkinElmer


• Merck Co


• Novartis


• Genentech


• AstraZenec a


• Eli Lilly and Company


• Myriad Genetics


• Roche Diagnostics


• LabCorp


• BioRad Laboratories


• Abbott Laboratories


• Quest Diagnostics

PARP Inhibitor Biomarkers Market Industry Developments

The PARP Inhibitor Biomarkers Market is anticipated to expand significantly between 2024 and 2032. The market is expected to witness substantial growth due to the rising prevalence of cancer and the increasing adoption of PARP inhibitors in cancer treatment. Furthermore, the development of novel PARP inhibitors and the expansion of their applications in various cancer types are contributing to the market growth. Key industry players are focusing on strategic collaborations and acquisitions to strengthen their market position and expand their product portfolios. Recent advancements in biomarker research and the growing adoption of personalized medicine approaches are also driving the demand for PARP Inhibitor Biomarkers Market.

PARP Inhibitor Biomarkers Market Segmentation Insights

• 
  

  PARP Inhibitor Biomarkers Market Cancer Type Outlook

  
  
  
  
  • Breast Cancer
  
  
  • Ovarian Cancer
  
  
  • Prostate Cancer
  
  
  • Lung Cancer
  
  
  • Other Cancers
  
  
  
  

• 
  

  PARP Inhibitor Biomarkers Market Biomarker Type Outlook

  
  
  
  
  • BRCA Mutations
  
  
  • PARP Expression
  
  
  • HRD Score
  
  
  • Other Biomarkers
  
  
  
  

• 
  

  PARP Inhibitor Biomarkers Market Application Outlook

  
  
  
  
  • Diagnosis
  
  
  • Prognosis
  
  
  • Treatment Selection
  
  
  • Monitoring
  
  
  • Other Applications
  
  
  
  

• 
  

  PARP Inhibitor Biomarkers Market End User Outlook

  
  
  
  
  • Hospitals
  
  
  • Diagnostic Laboratories
  
  
  • Pharmaceutical Companies
  
  
  • Research Institutions
  
  
  • Other End Users
  
  
  
  

• 
  

  PARP Inhibitor Biomarkers Market Technology Outlook

  
  
  
  
  • Immunohistochemistry (IHC)
  
  
  • Next-Generation Sequencing (NGS)
  
  
  • Fluorescence In Situ Hybridization (FISH)
  
  
  • Digital PCR
  
  
  • Other Technologies
  
  
  
  

• 
  

  PARP Inhibitor Biomarkers Market Regional Outlook

  
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa